Pharmac's fixed budget discourages use of cost-saving medicines common elsewhere.
Most of the $120m HNZ spent on consultants in FY24 went to the ‘big four’.
Blis has reported an increase in revenue and earnings despite a patent dispute.
NZ tech solutions 'won't scale and add cost and complexity'.
Editor
Followers will be emailed
articles by Victoria